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ABSTRAK 
 
KESAN  PENYEDIAAN  VITAMIN  E  KOMERSIAL  KE ATAS  
KETEGANGAN  SALURDARAH  DAN  PARAMETER KARDIOVASKULAR  
TERPILIH   
  
Vitamin E adalah antioksidan larut lemak yang dilaporkan mempunyai sifat 
antioksidan yang kuat.  Ia adalah antioksidan pemecah rantai utama pada tisu manusia, 
membran dan plasma. Vitamin E boleh dibahagikan kepada dua famili iaitu tokoferol 
dan tokotrienol, setiap famili pula boleh dibahagikan kepada empat isomer yang berbeza 
iaitu alfa, gama, delta dan beta tokotrienol dan tokoferol.  Matlamat tesis PhD ini adalah 
untuk menyiasat dengan lebih lanjut beberapa isu yang masih tidak diketahui tentang 
penggunaan vitamin E bagi kesihatan vaskular.   
 Kajian pertama tesis ini bermatlamat untuk menilai kesan alfa tokoferol pada 
komplians / ketegangan salurdarah, iaitu satu indeks kesihatan salurdarah, dalam 
sekumpulan subjek yang mempunyai risiko kardiovaskular yang tinggi tetapi belum 
mempunyai penyakit salurdarah. Kajian ini adalah kajian klinikal secara rawak, rabun 
dua belah, bersilang serta berkawalan plasebo melibatkan 20 wanita putus haid 
[menopaus] yang tidak mempunyai masalah perubatan. Sukarelawan diberi secara 
rawak sama ada plasebo atau 400 IU tokoferol setiap hari selama sepuluh minggu, 
sebelum rawatan disilangkan untuk sepuluh minggu lagi. Setiap lima minggu, wanita 
tersebut akan menghadiri sesi kajian pada waktu petang di mana pengukuran komplians 
salurdarah, tekanan darah dan kepekatan vitamin E plasma diambil. Purata umur wanita 
bagi kajian ini adalah  54.59±1.22 tahun.  Selepas 10 minggu rawatan, kepekatan 
vitamin E plasma adalah 24.22±2.1 μg/ml dan 11.89±0.68 μg/ml masing-masing apabila 
diberi vitamin E dan placebo (p<0.001). Tidak ada perbezaan bermakna antara nilai 
kelajuan gelombang denyutan [PWV] diperolehi selepas sepuluh minggu rawatan 
dengan tokoferol berbanding dengan placebo, nilai PWV ialah 9.04±0.29 m/s melawan 
 xix
9.14±0.29 m/s. Begitu juga, tiada perbezaan dilihat bagi tekanan darah sistolik dan 
diastolik di antara plasebo dan vitamin E  pada akhir minggu ke 10.   
  Dua kajian klinikal melibatkan tokotrienol telah dijalankan, bertujuan untuk 
mengkaji kesan dua persedian vitamin E kaya tokotrienol [TRE] yang berbeza terhadap 
komplians salurdarah manusia. Matlamat utama kajian tocotrienol yang pertama adalah 
untuk mengkaji kesan tiga dos persediaan biasa TRE terhadap komplians salurdarah 
yang dinilai menggunakan parameter PWV. Kajian ini adalah kajian klinikal rawak, 
rabun ukuran akhir [blinded end point] dengan kawalan plasebo berbentuk selari 
melibatkan 36 sukarelawan lelaki yang sihat. Pengukuran lain yang diambil adalah nilai 
‘augmentation index’ [AI], jumlah status antioksidan plasma [TAS], kepekatan vitamin 
E plasma, jumlah kolesterol [TC] dan lipoprotin kolesterol kepadatan rendah (low 
density lipoprotein cholesterol) [LDL-C] darah. Sukarelawan dibahagikan kepada empat 
kumpulan dan diberikan sama ada plasebo atau TRE pada dos 80 mg, 160 mg atau 320 
mg setiap hari selama dua bulan. Persediaan tokotrienol yang digunakan mengandungi 
34.56%, 24.63%, 15.00% dan 26.17% alfa, gama, delta tokotrienol dan alfa tokoferol 
masing-masing. Purata umur sukarelawan adalah 23.3±0.25 tahun. Tiada perbezaan 
bermakna dilihat di antara kumpulan dalam perubahan PWV dan AI [ANOVA, p=0.467 
dan p=0.092] akibat rawatan. Tiada juga perbezaan di antara kumpulan bagi parameter 
sampingan lain yang diukur. Walau bagaimanapun, kumpulan 160 mg menunjukkan 
pembaikan yang kecil tapi bermakna dalam parameter AI selepas rawatan berbanding 
dengan sebelum rawatan. Kapsul TRE yang digunakan dalam kajian ini boleh diterima 
dengan baik oleh sukarelawan.  
   Kajian  klinikal tokotrienol yang  kedua bermatlamat mengkaji kesan tiga dos 
persediaan khas vitamin E kaya tokotrienol [SF-TRE], [didakwa boleh meningkatkan 
penyerapan tokotrienol] ke atas komplians salurdarah. Kajian ini adalah kajian rawak, 
 xx
rabun ukuran akhir dengan kawalan placebo, berbentuk selari melibatkan 36 
sukarelawan lelaki yang sihat.  Pengukuran lain yang diambil ialah AI, TAS plasma, 
kepekatan vitamin E  plasma, paras TC dan LDL-C darah. Sukarelawan dibahagikan 
kepada empat kumpulan, setiap kumpulan diberi samada plasebo atau SF-TRE  secara 
oral pada dos 50 mg, 100 mg atau 200 mg setiap hari selama dua bulan. Persediaan SF-
TRE yang digunakan mengandungi 23.54%, 43.16%, 9.83%, 23.5% alfa, gama, delta 
tokotrienol dan alfa tokoferol masing-masing. Purata umur sukarelawan ialah 23.9±0.39 
tahun. Tiada perbezaan bermakna antara kumpulan dalam perubahan PWV dengan 
rawatan, perubahan setiap kumpulan masing-masing adalah -0.06±0.29, -0.44±0.20, 
 -0.77±0.19 dan -0.65±0.14 m/s untuk kumpulan plasebo, 50 mg, 100 mg dan 200 mg 
masing-masing [ANOVA, p=0.117].  Walau bagaimanapun, bagi kumpulan 100 mg dan 
200 mg, terdapat pembaikan bermakna dalam PWV selepas rawatan  dibandingkan 
sebelum rawatan [p=0.007 dan p=0.002].  Analisis varians [ANOVA] untuk perubahan 
AI selepas rawatan menunjukkan perbezaan bermakna atas sempadan [borderline] 
dengan nilai p=0.048. Perubahan nilai AI dengan rawatan adalah 2.22±1.54, -6.59±2.84, 
-8.72±3.77 dan -6.27±2.67 masing-masing bagi kumpulan plasebo, 50 mg, 100 mg dan 
200 mg. Analisis ‘post hoc’ menunjukkan nilai p atas sempadan pada 0.076 antara 
kumpulan placebo dan 100 mg. Semua kumpulan yang dirawat dengan SF-TRE 
menunjukkan pembaikan bermakna bagi parameter AI selepas rawatan dibandingkan 
dengan sebelum rawatan.  Tiada perubahan bermakna antara kumpulan bagi parameter 
lain yang diukur. Persedian SF-TRE yang digunakan dapat diterima dengan baik oleh 
sukarelawan.  
 Kesimpulannya, pengambilan 400 IU Vitamin E selama sepuluh minggu 
meningkatkan kepekatan alfa tokoferol plasma tetapi tidak memberi kesan pada 
komplians salurdarah bagi wanita putus haid.  Bagi vitamin E kaya tocotrienol, semua 
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kumpulan yang dirawat dengan persediaan TRE dan SF-TRE menghasilkan 
peningkatan bermakna bagi kepekatan alfa, gama dan delta tocotrienol dalam plasma. 
Persediaan TRE biasa tidak memberi kesan terhadap komplians salurdarah dalam 
sukarelawan lelaki sihat.  Secara keseluruhannya, SF-TRE juga tidak menunjukkan 
kesan bermakna ke atas komplians salurdarah. Walau bagaimanapun, terdapat arah 
kecenderungan [trend] terhadap pembaikan komplians salurdarah seperti yang 
dicadangkan oleh nilai bermakna atas sempadan [borderline significance] yang dilihat 
untuk pengukuran AI dengan SF-TRE. Pembaikan bermakna selepas rawatan, 
berbanding dengan sebelum rawatan [pembaikan dalam kumpulan] juga dilihat bagi 
semua kumpulan yang dirawat bagi parameter AI.  Kajian lanjut kesan TRE terhadap 
ketegangan salurdarah pada pesakit yang mempunyai masalah kardiovaskular yang 
nyata adalah dicadangkan.  
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ABSTRACT 
 
EFFECT OF COMMERCIALLY  AVAILABLE  VITAMIN  E  
PREPARATIONS ON ARTERIAL  COMPLIANCE  AND  SELECTED 
CARDIOVASCULAR  PARAMETERS  
 
 
              Vitamin E is a potent lipid soluble antioxidant. It is the principal chain breaking 
antioxidant in human tissues, membrane and plasma. Vitamin E comprised of two 
families, the tocopherols and tocotrienols, each family is further divided into the alpha, 
gamma, delta and beta isomers. This PhD thesis aimed to address some of the 
unresolved issues on vitamin E use in vascular health.   
             For tocopherol, a randomised, crossed over, double blind, placebo controlled 
clinical trial involving 20 healthy post menopausal women was conducted to assess the 
effect of alpha tocopherol on arterial compliance, an index of vascular health in a group 
of  high cardiovascular risk subjects who has no overt vascular disease. Subjects were 
randomised to either placebo or tocopherol 400 IU daily for ten weeks, before being 
crossed over for treatment for another ten weeks. At intervals of 5 weeks, subjects 
attended afternoon sessions where measurements of arterial compliance, blood pressure 
and plasma vitamin E level were taken. Mean age of these women were 54.59±1.22 
years. After 10 weeks treatment, plasma vitamin E level was 24.22±2.1 μg/ml and 
11.89±0.68 μg/ml respectively with vitamin E and placebo (p <0.001). There was no 
significant difference in pulse wave velocity [PWV] after ten weeks treatment with 
tocopherol compared to placebo, PWV values being 9.04±0.29 m/s versus 9.14±0.29 
m/s respectively. Similarly, no difference in systolic and diastolic blood pressures was 
seen between placebo and vitamin E at the end of ten weeks.  
For tocotrienols, two clinical trials were conducted. The first study was a 
randomised, placebo controlled, blinded end point clinical trial with a parallel design 
involving 36 healthy male subjects. This study aimed to determine the effects of a 
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normal preparation of tocotrienol rich vitamin E [TRE] on the primary parameter, 
arterial compliance as assessed by aortic femoral PWV.  Other measurements taken 
were augmentation index [AI], plasma total antioxidant status [TAS], plasma vitamin E 
levels, serum total cholesterol [TC] and low density lipoprotein [LDL-C].  Subjects 
were randomised to four treatment, either placebo or TRE at doses of 80 mg, 160 mg, or 
320 mg mixed tocotrienol daily for two months. The TRE contained 34.56%, 24.63%, 
15.00% and 26.17% respectively of alpha-tocotrienol, gamma-tocotrienol, delta 
tocotrienol and alpha-tocopherol. Mean age of subjects were 23.28±0.25 years. There 
were no significant differences between the groups in their change in PWV and AI with 
treatment [ANOVA, p=0.467 and p=0.092 respectively]. There were also no significant 
differences between groups in other measurements taken. Group 160 mg however, 
showed a small but significant improvement in AI after treatment compared to baseline.  
The TRE capsules used in this study were well tolerated by subjects. 
    The second clinical trial on TRE aims to determine the effect of three doses of 
a special formulation of tocotrienols (SF-TRE) [claimed to enhance tocotrienol 
absorption] on arterial compliance. This study was a randomised, placebo controlled, 
blinded end point clinical trial with a parallel design involving 36 healthy male subjects.  
Other measurements taken were AI, plasma TAS, plasma vitamin E levels, serum TC 
and LDL-C. Subjects were grouped into four groups, each group were prescribed either 
placebo, or SF-TRE at doses of either 50 mg, 100 mg, or 200 mg tocotrienols daily for 
two months. The SF-TRE contained 23.54%, 43.16%, 9.83%, 23.50% respectively of 
alpha, gamma, delta tocotrienol and alpha tocopherol. Mean age of subjects were 
23.86±0.39 years.  There were no significant differences between groups in their change 
in PWV with treatment; change for each group being -0.06±0.29, -0.44±0.20, -
0.77±0.19  and  -0.65±0.14 m/s  respectively  for  groups placebo, 50 mg, 100 mg  and  
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200 mg [p=0.117]. However, groups 100 mg and 200 mg showed significant 
improvement in PWV after treatment compared to baseline [p=0.007 and p=0.002]. 
Analysis of variance [ANOVA] for change in AI  treatment was of borderline 
significance at p=0.048, change for groups placebo, 50 mg, 100 mg and 200 mg being 
2.22±1.54, -6.59±2.84, -8.72±3.77 and -6.27±2.67 respectively. However, post-hoc 
analysis showed a borderline p value of  0.076 between groups placebo and 100 mg. All 
treated groups showed significant improvement in AI after treatment compared to 
baseline. There were no significant differences between groups in the other parameters 
measured. The SF-TRE used was well tolerated by subjects. 
  Conclusion: Supplementary vitamin E  for ten weeks at 400 IU daily increased 
plasma level of alpha tocopherol but has no effect on arterial compliance in healthy post 
menopausal women.  For tocotrienol rich vitamin E, treatment with all groups treated 
with TRE and SF-TRE produced significant elevations of alpha, gamma and delta 
tocotrienols. The conventional preparation of TRE did not have an effect on arterial 
compliance in healthy male subjects.  Overall, the SF-TRE also did not show significant 
effect on arterial compliance. However, there was a trend towards improvement in 
arterial compliance as suggested by the borderline significance value observed for the 
measurement of AI with SF-TRE. Significant within group improvement were also 
observed for all treated groups compared to baseline.  Future studies to investigate the 
effect of TRE on arterial stiffness in patients with clinically manifest cardiovascular 
disease is suggested. 
 
 
 
 
 
 
 
 
 1
CHAPTER 1  
 
 
INTRODUCTION 
 
1.1.        INTRODUCTION 
 
  Cardiovascular diseases, in particular coronary artery disease [CAD] are the 
most important cause of morbidity and mortality in developed countries [Tunstall-Pedoe 
et al., 1994]. In Malaysia, a developing country, cardiovascular diseases is the 
commonest cause of mortality in government hospitals, accounting for 24.5% of all 
deaths for the year 1998. Coronary artery disease is the major cause of these deaths 
[National Heart Association of Malaysia, 2001]. Stroke is another devastating 
cardiovascular illness and is the most common cause of severe disability in Malaysian 
adults [Academy of Medicine of Malaysia and Ministry of Health Malaysia, 2000]. The 
average incidence of stroke is about 2:1,000 population, this risk increases with age 
such that after the fifth decade, the incidence doubles with every decade of life. Every 
year about 2,500 deaths and 12,000 stroke discharges are recorded in government 
hospitals 
 
 Atherosclerotic plaque formation has been reported to be the underlying basis 
for CAD, besides contributing to the occurrence of stroke.  The plaque consists of a 
collection of variable amounts of cholesterol, smooth muscle cells, fibrous tissue and 
inflammatory cells in the intima, separated by fibrin cap from the flowing blood in the 
arterial lumen [Yusoff, 2002].  The plaque often grows with time, gradually narrowing 
the coronary lumen.  This progressively decrease and reduce the blood supply to 
myocardial tissues supplied by the coronary artery.  When a critical narrowing of the 
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coronary lumen eventually occurs, [with approximately 70% diameter reduction], 
myocardial ischemia occurs, manifested clinically as angina pectoris. Initially, angina 
occurs on exertion, because it  is on exertion that the blood supply, restricted in a fixed 
manner, is not able to provide the increased demand for blood supply to nourish tissues 
requiring more energy during  exertion.  
 
 Later, acute myocardial infarction and unstable angina may occur, as a result of 
plaque rupture and abrupt coronary occlusion due to acute thrombus formation which is 
made worse by a coronary stenosis.  Inflammation has recently been reported to further 
contribute towards plaque formation and rupture [Greaves and Channon, 2002; Shah, 
2000].  
 
 Free radicals are widely reported to contribute to the development of 
atherosclerotic plaque and vascular diseases [Parthasarathy et al., 1999; Gackowski et 
al., 2001; Juliano, 2001]. Free radicals are molecules with one or more unpaired 
electrons, which are usually highly reactive towards bio molecules. Free radicals are 
involved in the formation of oxidised low density lipoprotein [LDL-C], which 
contributes to the formation of atherosclerotic plaques. Oxidised LDL-C, not un-
oxidised LDL-C, is engulfed by intimal macrophages, transforming them into foam cells 
which develop into fatty streaks, the precursors of the atherosclerotic plaque. Foam cell 
formation also leads to endothelial injury and dysfunction. This further facilitates 
passage of LDL-C from the flowing blood into the intima accelerating the process of 
vascular damage [Steinberg et al., 1989]. In atherosclerosis, oxidised LDL-C 
accumulates in the vascular wall [Yla-Herttuala et al., 1989], where it is cytotoxic 
[Morel et al., 1983] and chemotactic for monocytes [Quinn et al., 1987]  leading to the 
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accumulation of vascular inflammatory cells and perhaps, the production of free radical 
that can inactivate endothelium derived nitric oxide [Stouffer et al., 2002]. 
 
 The body has a number of mechanisms to control the production of radical 
oxygen species [ROS] and to limit or repair damaged tissues. In healthy individuals, the 
antioxidant system defends tissues against free radical attack. The body’s antioxidants 
may be endogenously produced or derived from the diet.  These antioxidants may be 
present in cells, including their membranes or in extracellular fluids, which may be 
hydrophilic such as ascorbic acid, or hydrophobic such as vitamin E. 
 
 Antioxidants may act at several different stages in the oxidative sequence, for 
example it can remove ROS, scavenge initiating free radicals, break the chain reaction 
of an initiated sequence or scavenge and quench singlet oxygen [Young and Woodside, 
2001].  Because of the contribution of free radicals to plaque formation and vascular 
diseases, and the ability of antioxidants to neutralise these radicals, the relationship 
between antioxidants and cardiovascular incidence is intriguing to many. This prompted 
a lot of work in this field, looking at the relationship between plasma antioxidant levels 
and cardiovascular diseases, and the effect of antioxidant supplementations to 
cardiovascular diseases.   
 
   The most abundant lipid soluble antioxidant in human plasma is vitamin E 
[Burton et al., 1983] and the oxidation of LDL-C in vitro is limited by vitamin E 
[Reaven et al., 1993]. Thus vitamin E has received much attention for its role in 
cardiovascular and vascular pathology. In vitro studies had shown that increased 
resistance to oxidation of LDL-C  was achieved when they were enriched with an 
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antioxidant, such as vitamin E  [Esterbauer et al., 1991; Jialal and Grundy, 1992; Abbey 
et al., 1993; Reaven et al., 1993; O’Byrne et al., 2000].  This was supported by animal 
studies, where it had been shown that vitamin E reduce plaque formation and lead to 
plaque stabilisation [Black et al., 2000, Qureshi et al., 2001a].  
 
  Supplementary vitamin E is effective in reducing the progression of 
atherosclerosis in subjects with previous coronary artery bypass graft surgery not treated 
with lipid-lowering drugs [Kritchevsky et al., 1995].   Large prospective cohort studies 
have demonstrated that intake of vitamin E from certain foods and supplements were 
associated with a reduced risk of  major coronary events in postmenopausal women and 
subjects  above the age of forty [Rimm et al., 1993; Stampfer et al., 1993; Kushi et al., 
1996].   A secondary prevention study in patients with CAD showed a 77% reduction in 
nonfatal myocardial infarction can be achieved with 400-800 IU alpha tocopherol daily 
over a median follow up period of 510 days [Stephens et al., 1996].  However, results 
from more recent large interventional clinical trials [Rapola et al., 1997; GISSI- 
Prevenzione Investigators, 1999; The Heart Outcomes Prevention Evaluation Study 
Investigators, 2000; Collins et al., 2002] had not shown benefits conferred by vitamin E 
supplementation, suggesting that vitamin E has no role in protecting against 
cardiovascular events.  
 
  Despite numerous work conducted on vitamin E, there are, however, some 
unanswered questions on the role of vitamin E in cardiovascular diseases. This thesis 
consists of three randomised clinical trials, designed to address some of the unresolved 
issues of vitamin E and its vascular effect.  Why is there a need to re-look at vitamin E 
and vascular protection? 
 5
             Firstly, the above mentioned large intervention randomised studies were 
conducted on high risk populations; in populations with known pre-existing vascular 
diseases or those with history of diabetes or hypertension [Rapola et al., 1997; GISSI 
Prevenzione Investigators, 1999; The Heart Outcomes Prevention Evaluation Study 
Evaluation Investigators, 2000; Collins et al., 2002].  The observation that vitamin E did 
not confer cardiovascular protection in those studies may be because the trials were 
conducted relatively late in the disease process. The protective effects of dietary vitamin 
E  may be more evident earlier in the disease process; at a time when pre-atherosclerotic 
vascular changes first become  manifest  and are more likely to be  susceptible to 
modifications. The effects of vitamin E on cardiovascular events, in lower risk 
populations have not been well studied. One major problem of conducting a 
cardiovascular outcome study in a low risk group is the very large sample size needed 
for such a study. This is because of the low expected incidence of cardiovascular events 
in this group.  Measuring effect of vitamin E on arterial compliance is one way to assess 
its effect on arterial function before vascular disease is established. This is because 
arterial compliance had been shown to be dependent on endothelial function [Ramsey et 
al., 1995].  The endothelium produces endothelium derived relaxing factor [EDRF] that 
helps maintain vascular relaxation which maintains vascular compliance and decreases 
arterial stiffness.  The endothelium may also cause changes in smooth muscle tone that 
affects arterial compliance. Endothelial dysfunction is an early precursor for vascular 
damage.  Changes in endothelial function had been shown to predate the development 
of pathological vascular states [Anderson, 1999]. Reduced arterial compliance is also 
associated with coronary artery disease [Dart et al., 1991] as well as with various 
cardiovascular risk factors including age, arterial blood pressure [Dart and Qi, 1995], 
diabetes [McVeigh et al., 1994], and LDL cholesterol levels [Tanaka et al., 1998]. 
 6
Arterial stiffness is a strong predictor of cardiovascular events.  In the elderly patients, it 
is a strong predictor of cardiovascular mortality [Meaume et al., 2001].  In hypertension, 
arterial compliance was shown to be an independent predictor of both cardiovascular 
and all cause mortality [Laurent et al., 2001].  The same is true for type 2 diabetes and 
individuals with impaired glucose tolerance [Cruickshank et al., 2002].   
 
 Thus the effect of tocopherol on arterial compliance in healthy post menopausal 
women formed the first randomised clinical trial of this thesis. Menopausal women were 
chosen as they are known to have higher risk of cardiovascular events compared to pre-
menopausal women. Healthy menopausal women were chosen as these women have not 
had established vascular pathology, thus enabling us to study the effect of tocopherol on 
vascular function in a high risk cardiovascular group before vascular disease 
manifestation. 
 
    Secondly, there are two classes of commercially available vitamin E in the 
market, tocopherol and tocotrienol. All the above observational and large randomised 
clinical trials used tocopherol as the vitamin E. This may be due to tocopherol being the 
vitamin E that was first discovered in 1922 [Evans and Bishop, 1922].  Furthermore, 
tocopherol vitamin E is much more easily available in the Western parts of the world 
where most of these studies were done. They can be obtained from vegetable and seed 
oil sources such as soybean, safflower and corn, sunflower seeds, nuts, whole grains and 
wheat germ.  These sources of vitamin E predominantly contain alpha tocopherol with 
insignificant amounts of tocotrienol. It was only recently that tocotrienol was 
discovered.  Tocotrienols are the major vitamin E in palm oil and rice bran; these two 
 7
sources contain tocotrienol as the predominant vitamin E.  The palm oil is the highest 
source of natural tocotrienol [Watkins et al., 1999; Packer et al., 2001].  
 
  Tocotrienols had been reported in vitro, to have higher antioxidant properties 
compared to alpha-tocopherol [Serbinova et al., 1991; Suzuki et al., 1993].  Tocotrienol 
was also reported to have another potentially beneficial property in reducing 
cardiovascular diseases, the potential to lower serum lipid levels.  In vitro [Pearce et al., 
1992, Parker et al., 1993] and experimental studies [Qureshi et al., 1991a; Qureshi et 
al., 1996; Qureshi et al., 2001a] had shown that tocotrienols inhibit 3 hydroxy-3-
methylglutyryl-coenzyme A reductase [HMG-CoA reductase],  the enzyme responsible 
for in vivo cholesterol synthesis. These two properties of tocotrienol, potent antioxidant 
and lipid lowering potential, may give a more favourable effect on arterial health and 
cardiovascular events compared to tocopherol.  
  
   When literature search was first commenced for this thesis [approximately four 
years ago], a lot was not known on tocotrienols. Most studies conducted on tocotrienols 
were in vitro or animal work.  There were minimal human studies on tocotrienols, 
which will be reviewed in Chapter 2. Certainly there are no large randomised trials on 
tocotrienols.  There are no studies on the effect of tocotrienol rich vitamin E on 
cardiovascular events.  Most human clinical studies with tocotrienols looked at the lipid 
lowering effect of tocotrienols. Even so, the doses that had been used in these clinical 
studies vary widely, ranging between 40 mg/day to 240 mg/day with no clear guidelines 
on the doses of tocotrienols to be used. Although the effect of tocotrienols on lipid 
peroxidation in humans had been reported [Tomeo et al., 1995; Ismail et al., 2002], 
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there were no human studies that assessed the effect of tocotrienols on the plasma total 
antioxidant status, i.e the ability of plasma to quench generation of free radicals. 
 
  Thus the second clinical trial of this thesis investigated a few unanswered 
issues on tocotrienol by looking at the effects of different doses [low, medium and high] 
of palm tocotrienol rich vitamin E [TRE] on selected cardiovascular parameters with the 
primary end point being arterial compliance.  Free radicals had been shown to inactivate 
endothelium derived relaxing factors [EDRF], the substance that causes vasorelaxation 
thus helping to maintain vascular compliance. Antioxidants may help in quenching 
these free radicals, preserving the effect of EDRF on the vessel compliance. Other 
parameters such as the effects of graduated doses of TRE on steady state blood levels of 
vitamin E, plasma antioxidant and lipid profile were also measured. Adverse effects and 
tolerability of subjects to the doses used were also studied, as 320 mg daily of TRE was 
the highest dose reported so far in the literature at that time.  
 
    The absorption of tocotrienols, being fat soluble vitamins, were known to be 
highly variable and dependent on the physiological processes in the stomach and small 
intestines. The absorption of fat soluble vitamins are induced by food, especially fat 
intake [Yap et al., 2001].  Only with sufficient food and fat intake will there be 
sufficient pancreatic juice and bile secreted to emulsify the tocotrienols for satisfactory 
absorption.  Since factors like food and fat intake tend to be variable, the absorption of 
tocotrienols will also be variable.  A special formulation of tocotrienol rich vitamin E 
[SF-TRE] which claimed to be able to provide 200-300% higher absorption than the 
normal preparation was launched fairly recently. These capsules were reported to be 
able to self emulsify to form a readily absorbable form of tocotrienol in order to increase 
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tocotrienol bioavailability and thus their blood levels. Theoretically, tocotrienol 
absorption from this formulation will not be dependent on the physiological 
mechanisms of the stomach like pancreatic juice and bile secretion. Thus its absorption 
should be less affected by food intake. Therefore the third clinical trial of this thesis was 
conducted to assess if the special formulation tocotrienols [SF-TRE] has enhanced 
pharmacodynamic effect consequent to increased blood levels. The pharmacodynamic 
effects of interest are those on cardiovascular parameters similar to the second clinical 
trial.   
 
 In summary, this thesis is composed of 3 randomised, placebo controlled 
clinical trials to address some of the unknown issues on the role of vitamin E in vascular 
health. The first study investigates the effect of a commercially available alpha 
tocopherol daily on arterial compliance in healthy postmenopausal women, a group 
known to have less compliant [stiffer] arteries compared to pre-menopausal women. 
The second clinical trial investigates the effect of varying doses of a marketed normal 
preparation of TRE on arterial compliance in healthy volunteers. The third clinical trial 
also investigates the effect of varying doses of a self emulsifying preparation of TRE on 
arterial compliance in healthy volunteers.  Secondary parameters such as plasma total 
antioxidant status, serum total cholesterol and low density lipoprotein levels were also 
performed in the second and third clinical trials as secondary end points. Tolerability 
and adverse effects of these formulations were also investigated.  Plasma vitamin E 
levels were performed to ensure compliance and absorption of the vitamin E by study 
subjects.  This is to confirm that any effects seen during treatment were due to the 
vitamin E consumption. 
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1.2.    AIMS  OF  THIS  THESIS 
 
1. To assess the effect of natural alpha tocopherol on arterial compliance in post 
menopausal women without overt vascular pathology.  
 
2. To assess the effect of three doses of normal preparation of tocotrienol rich 
vitamin E [low, medium and high] on arterial compliance in healthy volunteers. 
Secondary outcomes are plasma total antioxidant status, serum total cholesterol 
and low density lipoprotein levels.  
 
3. To assess the effect of three doses [low, medium and high] of a self emulsifying 
formulation of tocotrienol rich vitamin E on arterial compliance in healthy 
volunteers. Secondary outcomes are plasma antioxidant status, serum total 
cholesterol and low density lipoprotein levels.  
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CHAPTER 2 
 
LITERATURE  REVIEW 
 
2.1       INTRODUCTION TO FREE RADICALS 
 
Free radicals are molecules with one or more unpaired electrons, which are 
usually highly reactive towards bio molecules [Abuja and Albertini 2001]. Free radicals 
can react with cell components causing damage. Free radicals formed in the body are 
the result of metabolic reactions (such as mitochondrial electron transport chain and 
oxidative enzyme reactions) as well as exposure to environment toxins such as 
ultraviolet light, cigarette smoke, ionising radiation and other pollutants. Among the 
main free radical species which occur in the human body include superoxide radicals, 
hydroxyl radicals, nitric oxide radical and peroxyl radicals. Free radicals modify 
endogenous molecules (such as proteins, lipids and deoxyribonucleic acid) when the 
unpaired electron of the free radical removes an electron from the target molecule. In 
some cases, the product of this initial oxidation reaction will cause subsequent oxidation 
of other molecules, thus propagating an oxidation chain reaction [Young and Woodside 
2001].   The relative effect of a free radical depends on the type that is generated and the 
biological tissue in which the reaction takes place [Stouffer et al., 2002].  Free radicals 
have been suggested to be either directly or indirectly involved in a wide variety of 
clinical disorders such as atherosclerosis [Yla-Herttuala et al., 1989], cancer, 
reperfusion injury, diabetes and Parkinson’s disease among others [Knight, 1995; Abuja 
and Albertini, 2001]. 
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2.1.1   Free radicals and cardiovascular diseases  
 
  There are three mechanisms proposed by which oxidative damage from free 
radicals could contribute to cardiovascular diseases especially coronary heart disease. 
The first is through direct damage that free radicals may cause to cells and molecules. 
The second is through its role on endothelium dependent vasorelaxation. The third 
recently proposed mechanism is via participation of free radicals in specific cell 
signalling pathways.  
 
  With regard to the molecular and cell damage caused by free radicals, a major 
area of interest is the oxidative modification of LDL-C. This has been proposed as a 
possible explanation for the relationship between LDL-C and atherosclerosis [Steinberg 
et al., 1989]. Low density lipoprotein cholesterol is a collection of cholesterol, 
cholesterol esters and triglycerides surrounded by a matrix of phospholipids and 
apolipoproteins. Free radicals have the capability to oxidise LDL-C, resulting in 
numerous changes that could potentially contribute to atherogenesis [Parthasarathy et 
al., 1999]. Support for involvement of oxidised LDL-C in atherogenesis came from the 
demonstration that LDL-C extracted from atherosclerotic plaques formed in vivo is 
similar to LDL-C that was oxidatively modified in vitro [Yla-Herttuala et al., 1989].  
 
  Oxidised LDL-C had been shown to accelerate several steps in atherosclerosis 
including endothelial damage, monocytes / macrophage recruitment, rapid uptake of 
oxidised LDL-C by monocytes / macrophage scavenger receptors, alteration in vascular 
tone and induction of growth factors.  Oxidised LDL-C affects growth, proliferation, 
and death of cells in the arterial wall [Stouffer et al., 2002].  Oxidised LDL-C is 
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recognised by scavenger receptors on the macrophages.  The macrophages take up the 
oxidatively modified LDL-C in an unregulated manner causing accumulation of large 
amounts of lipids from oxidised LDL-C in the macrophages. These lipid rich 
macrophages are eventually converted into foam cells, which are the hallmark of the 
atherosclerotic fatty streak. This early fatty streak is the precursor lesion that 
subsequently leads to the development of the intermediate and the final complicated 
lesion of atherosclerosis.  
            
  In addition to LDL-C, oxidative modification of other molecules such as nitric 
oxide is also thought to impact on cardiovascular diseases.  An endothelium derived 
relaxing factor [EDRF], identified as nitric oxide [NO] is an important substance 
involved in the local control of vascular tone and platelet adhesion to the endothelial 
surface. Atherosclerosis had been shown to be associated with abnormalities in 
endothelium dependent arterial relaxation that may, in part result from the effects of 
oxidised LDL-C on endothelium derived NO. Modified LDL-C inhibits receptor 
mediated endothelium dependent arterial relaxation [Kugiyama et al., 1990] and 
degrades endothelium derived NO directly [Chin et al., 1992].   A variety of free 
radicals can also interact with and degrade nitric oxide produced by the endothelial wall, 
thereby impairing endothelium dependent vasorelaxation [Cai and Harrison, 2000].  
Loss of coronary vasorelaxation function had been correlated with a worse prognosis for 
cardiovascular events [Schachinger et al., 2000].  
  
  Recently, there is growing research interest in investigating the role of free 
radicals in cellular signalling pathways involved in cardiovascular disease processes 
[Griendling et al., 2000].  This includes the cell capacity to exert control over intra and 
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extra cellular oxidative stress through the specific production and metabolism of free 
radicals. Because many of these signal transduction pathways play a role in 
cardiovascular physiology, this provides another possible link between oxidative stress 
and cardiovascular disease. For example free radicals may be involved in activating 
protein kinase C in vascular smooth muscle cells.  Protein kinase C activation had been 
implicated in vascular disease due to diabetes [Tesfamariam et al., 1991] and oxidised 
LDL-C [Ohgushi et al., 1993].  Free radicals may also be involved in influencing 
leucocyte adhesion to endothelial cell, monocyte transmigration, and oxidant mediated 
toxicity. The redox sensitive pathways control a wide range of cellular functions, 
including the expression of cell surface markers, cellular growth and apoptosis.  
 
2.1.2      Antioxidants 
 
  Antioxidants are defined as substances or compounds that significantly delays, 
prevents or reduce oxidation of that substrate [Abuja and Albertini, 2001]. There are 
generally three categories of antioxidants; antioxidant enzymes, chain breaking 
antioxidants and preventive antioxidants [Maxwell and Lip, 1997; Young and 
Woodside, 2001].  
 
  Antioxidant enzymes catalyse reactions involved in the conversion of free 
radicals to oxygen and water. They include the catalase, glutathione peroxidase and 
superoxide dismutase. The chain breaking antioxidants prevent propagation of oxidative 
chain reactions by terminating free radicals or the reactive products of molecules that 
have been damaged by free radicals. Lipid soluble chain breaking antioxidants include 
vitamin E, beta carotene, vitamin A (for which beta carotene is the precursor), the 
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flavonoids, and ubiquinol-10 (the reduced form of coenzyme Q10). Water soluble chain 
breaking antioxidants include vitamin C, uric acid, bilirubin bound to albumin, and the 
thiol groups of plasma proteins such as albumin.  The preventive antioxidants are the 
metal binding proteins that function to sequester free iron or copper to prevent 
production of the hydroxyl radical from other free radicals. These include ferritin, 
transferrin, lactoferrin and ceruloplasmin [Stouffer et al., 2002].  
 
   In the plasma, major antioxidant defences include vitamin C, protein thiols, 
bilirubin, urate and alpha tocopherol. Plasma also contains the ‘preventive’ antioxidants, 
ceruloplasmin and transferrin, the iron scavenging proteins whose contribution to the 
total antioxidant capacity is to prevent iron availability [Young and Woodside 2001].   
 
  Because of the role free radicals are believed to contribute to the pathogenesis 
of atherosclerosis and cardiovascular diseases, antioxidant represent a promising, but 
yet unproven means of decreasing atherosclerosis and coronary artery disease. 
Postulated mechanisms whereby antioxidants could protect against cardiovascular 
diseases were derived from basic research demonstrating ability of antioxidants to 
inhibit oxidation of LDL-C [Abbey et al., 1993], atherosclerosis development and 
progression [Black et al., 2000; Qureshi et al. 2001b] and preventing endothelial 
dysfunction [Anderson et al., 1994; Stewart-Lee et al., 1994; Keaney et al., 1996].  
Because antioxidant vitamins are part of the body’s nutrient needs, and are considered 
safe substances, they have generated a lot of interest as supplements that could 
potentially be beneficial in cardiovascular health. 
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  Vitamin E is an antioxidant vitamin that has received a lot of attention as a 
possible means of preventing and / or reducing cardiovascular diseases. This partly 
stems from the fact that it is the principal lipid soluble chain breaking antioxidant in 
human tissues, membrane and plasma [Machlin, 1991; Traber and Sies, 1996].  It is also 
a major lipid soluble chain breaking antioxidant that prevents the propagation of free 
radical reactions in membranes and lipoproteins [Azzi, 2004].  It was also reported to be 
the predominant antioxidant in the LDL-C particle [Esterbauer et al., 1991a].  
             
       
2.2         INTRODUCTION TO VITAMIN E  
 
  Vitamin E, in the form of alpha tocopherol was discovered in 1922 by Evans 
and Bishop, as a factor essential for reproduction [Evans and Bishop, 1922].  Lack of 
this factor in rats caused ‘infertility’ in male rats and increased risk of miscarriage / 
abortion in female rats.  The name tocopherol then came from the Latin word ‘tokos’ 
(childbirth) and ‘phorein’ (to bring forth).  The suffix ‘ol’ was added at the end to 
indicate the phenolic nature of the substance [Kamal Eldin and Appelqvist, 1996].  
  
  Nowadays, the term vitamin E is used as the collective name for the eight 
naturally occurring molecules [four tocopherols and four tocotrienols] which 
qualitatively exhibit the biological activity of alpha tocopherol.  Vitamin E occurs in 
nature in at least eight different isoforms: alpha, gamma, delta and beta tocopherols and 
alpha, delta, gamma and beta tocotrienols [Packer et al., 2001].  The eight isomers of 
vitamin E share some important traits.  Firstly, all have a head or chroman ring in 
technical term. Secondly, all have a ‘tail’, which is called the phytyl tail for tocopherols.  
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Thirdly, all have the hydroxyl group, which is the active group on the head of the 
molecule. Tocotrienols differ from the corresponding tocopherols only in their aliphatic 
tail.  Tocopherols have a phytyl side chain attached to their chromanol nucleus, whereas 
the tail of tocotrienol is unsaturated and forms an isoprenoid chain. The tocotrienol tail 
has three double bonds while the tocopherol tail has none.  The gamma, delta and beta 
isoforms of tocotrienols and tocopherol differ by the number [alpha has 3, beta and 
gamma have 2, while delta has 1] and position of their methyl groups on the chromanol 
nucleus [Traber et al., 1997; Packer et al, 2001].  The structures of tocopherol and 
tocotrienols are illustrated in figure 2.1 
 
2.2.1.     Source and requirements of  vitamin E 
 
  Lipid rich plant products and vegetable oils are the main natural sources of 
vitamin E.  These include nuts, wheat germ, sunflower, safflower, palm oils, rice bran 
and others.  Tocopherols are present in polyunsaturated vegetable oils and in the germ 
of cereal seeds.  Tocotrienols are found in high concentrations and is the predominant 
vitamin E in palm oil, barley and rice bran [Theriault et al., 1999].  Approximately 70% 
- 75% percent of the vitamin E content in palm oil consists of tocotrienol isomers, while 
the rest are alpha tocopherol.  Palm oil was reported to be the richest source of 
tocotrienols in nature [Tan, 1989].  Other cooking oils such as corn oil, soy and 
sunflower oils are good sources of tocopherol but contain no tocotrienols. 
  
 Vitamin E is included as one of the body’s essential nutrient which must be 
obtained either from dietary intake or as a supplement.  The recommended daily dietary  
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Figure 2.1 
 
The molecular structures of the different isomers for tocopherol and tocotrienol.  
 19
allowance [RDA – USA] for this vitamin is 10 mg for adult males and 8 mg for adult 
females [Meydani, 1995].  These recommended dietary allowances for vitamin E define 
the human requirement only for alpha tocopherol [Packer et al., 2001]. 
 
2.2.2      Pharmacokinetics of vitamin E 
 
2.2.2.1   Pharmacokinetics of tocopherol  
 
  The hydrophobic nature of vitamin E necessitates a special transport system for 
this substance in the aqueous phase of plasma, body liquids and cells.  The fractional 
absorption of vitamin E in humans has been estimated to be between 60-70% [Kelleher 
and Losowsky 1970;  MacMahon and Neale, 1970].  Bile acids are secreted by the liver 
into the small intestine where they function to aid in digestion of dietary fat.  Absorption 
of vitamin E from the proximal intestine depends on the amount of lipid / fat in the 
food, bile acids and pancreatic juices.  Vitamin E emulsifies with lipid soluble 
components in the food forming micelles that can be passively absorbed in a non 
saturable process into the mucosa cells mainly at the proximal parts of the intestine 
[Meydani, 1995].  Absorption therefore is facilitated by a liberal intake of fat. 
 
   Upon uptake into intestinal cells, together with triglycerides, phospholipids, 
cholesterol and apolipoproteins, vitamin E are reassembled into chylomicrons by the 
Golgi apparatus in the mucosal cells [Traber et al., 1986].  Chylomicrons are excreted 
by exocytosis into the lymphatic system to reach the blood [Kayden and Traber, 1993; 
Ikeda et al., 1996].  Chylomicron lipolysis, facilitated by the enzyme lipoprotein lipase, 
allows part of vitamin E to be distributed to tissues.  The remaining chylomicron 
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remnants deliver the remaining alpha tocopherol to the liver.  Inside the liver, vitamin E 
is incorporated into liposomes.  Uptake of vitamin E into liposomes is non specific, but 
there is a specific transport protein to alpha tocopherol, that is the α-tocopherol transfer 
protein [α –TTP] which is sized at 32 kDA.  Alpha–TTP transports alpha tocopherol 
from liposomes into lipoproteins especially Very Low Density Lipoprotein [VLDL] 
before the liver cells secrete VLDL into the blood stream for distribution into other 
organs [Stocker and Azzi, 2000].  VLDL helps transport and delivers alpha tocopherol 
to peripheral cells [Bjorneboe et al., 1990].  
 
   Secretion of alpha tocopherol in VLDL can lead to the enrichment of all 
circulating lipoproteins with alpha tocopherol [Kayden and Traber, 1993, Bjorneboe et 
al., 1990].  Upon secretion into the plasma, the VLDL is catabolised by the lipoprotein 
lipase and returned to the liver, while the remainder are converted in the circulation to 
LDL-C.  Alpha tocopherol that is secreted from the liver in VLDL can have alternative 
fates.  Some of the alpha tocopherol can be transferred to High Density Lipoprotein 
cholesterol [HDL-C]  during lipolysis, some can travel with the VLDL core during 
conversion to LDL-C, and some can return to the liver as VLDL remnants [the 
intermediate density lipoprotein].  Thus, it can be appreciated here that the plasma 
transport of tocopherol is mainly by plasma lipoproteins especially via LDL-C and 
HDL-C in association with plasma surface components.  In terms of mass distribution of 
tocopherol among lipoproteins in humans, the percentages of tocopherol transported by 
the respective lipoproteins had been reported to be VLDL 19%, intermediate density 
lipoprotein [IDL] 3%, LDL-C 42% and HDL-C 36%.  However, plasma vitamin E is in 
a constant state of flux between the lipoproteins.  The transport of vitamin E from 
peripheral tissues to the liver has not been studied extensively.  
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  Alpha-TTP gene mutation results in low serum and cell alpha tocopherol.  
Thus, the two factors needed for realising an adequate level of alpha tocopherol in the 
body are dietary availability and the expression of liver α-TTP.  Alpha-TTP is also 
expressed in tissues including the trophoblast region of placenta.  The α-TTP probably 
plays an important role in supplying the vitamin to the foetus, and explains the foetal 
resorption occurring in rats fed a vitamin E deficient diet.  Plasma phospholipid transfer 
protein facilitates the exchange of tocopherol between LDL-C and HDL-C.  Alpha 
tocopherol that is bound to lipoprotein is transported from the blood into cells with the 
help of the scavenger receptor B1 [SR-B1] [Kayden and Traber, 1993]. In the cells, 
alpha tocopherol is placed into cell membrane components including mitochondria and 
the endoplasmic reticulum [Machlin, 1991].  
    
 Dimitrov [1991] had reported that after single administration of alpha 
tocopherol, the plasma concentrations peaked at between 12 to 24 hours.  With chronic 
administration for 28 days, doses at 440 IU, 880 IU and 1200 IU resulted in a steady 
state that occurred by days four to five of supplementation.  This was consistent with the 
reported plasma half life of alpha tocopherol being approximately 20 hours.  Dimitrov 
also reported that the plasma elevation of alpha tocopherol was affected by dietary fat 
intake.  Individuals consuming a high fat diet showed significantly greater plasma alpha 
tocopherol concentrations compared with those fed a low fat diet. This is explained by 
alpha tocopherol being a fat soluble vitamin, thus its absorption will be affected by 
dietary lipids and bile in the gastrointestinal tract.  
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2.2.2.2.    Pharmacokinetics of tocotrienol 
 
     The fate of supplemented tocotrienols and the relationship between its 
intestinal absorption, blood levels and tissue distribution is still not well studied 
[Watkins et al.,1999].  Some investigators even had difficulties in detecting plasma 
tocotrienols before and after supplementation.   For example Khor et al. [1995] reported 
that guinea pigs treated with different dosages of tocotrienols for six days had only 
alpha tocopherol and no tocotrienols in their serum.  Tomeo et al. [1995] did not 
manage to detect plasma tocotrienols after supplementation with 240 mg daily of TRE 
to patients with carotid stenosis and hypercholesterolemia.  Hayes et al. [1993] also 
reported that in fasting humans, the plasma tocotrienol concentration was not increased 
significantly after tocotrienol supplementation. 
 
                In studies using thoracic duct cannulated rats, Ikeda et al. [1996] showed that, 
similar to alpha tocopherol, alpha, delta and gamma tocotrienols were transported via 
the lymphatic system after oral absorption.  This is because they are too lipophilic to be 
absorbed via the hepatic portal vein. They also reported that alpha tocotrienol was 
preferentially absorbed compared with delta and gamma tocotrienols.  Hayes et al. 
[1993] suggested that tocotrienols are transported non-specifically like any lipid soluble 
compound, most likely being incorporated with triglyceride in the core of the 
triglyceride rich chylomicrons.  Once transported to the adipose tissue, a modest level of 
tocotrienols especially gamma tocotrienols appears to be deposited and stored with the 
triglycerides, presumably to be released during lipolysis.  Unlike alpha tocopherol, 
which has a cytosolic binding protein in the liver to sequester and enhance their 
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conservation and re-secretion into lipoproteins, no similar transport / binding protein 
have been found as yet for tocotrienols. 
 
    The pharmacokinetics and bioavailability of alpha, gamma and delta 
tocotrienols under fed and fasted conditions were studied in eight healthy volunteers 
[Yap et al., 2001] after a single dose of 300mg mixed tocotrienols composed of 
approximately  56.1%, 29.4%, 14.4% and 31.5% respectively of gamma,  alpha and 
delta tocotrienol and alpha tocopherol. Absorption of tocotrienols was markedly 
increased and also more consistent when taken with food.   Peak plasma concentrations 
for alpha, gamma and delta tocotrienol were reported to be achieved at 4.3 hrs after 
dosing for alpha and gamma tocotrienol and at 3.9 hours after dosing for delta 
tocotrienol [Yap et al., 2001].  Plasma concentrations of all tocotrienols increased 
markedly when dosed with food; mean maximum concentration [Cmax] and area under 
the curve [AUC] values for all tocotrienol isomers for the fed state were higher 
compared with the values of the fasted state.  This is because absorption of fat soluble 
vitamins in general, requires emulsification by bile salts before transportation across the 
gut mucosa.  A high fat diet causes stimulation of bile secretion, which may thus 
explain the increased absorption of tocotrienol in the fed state.  Mean elimination half 
life of alpha tocotrienol, gamma and delta tocotrienols were 4.4, 4.3 and 2.3 hours 
respectively.  These are between 4.5 – 8.7 fold shorter than that for alpha tocopherol, 
which have a half life of about twenty hours.  There were no significant differences in 
the plasma half life of the tocotrienol isomers when supplementation was given in the 
fed or fasted state.  The volume of distribution of tocotrienol [Vd] appeared to be 
relatively big, which the authors reported may be indicative of either incomplete 
absorption or extensive redistribution from the blood or both.  
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    Plasma transport of tocopherol is mainly by plasma lipoproteins, especially 
LDL-C and HDL-C.  However, the exact plasma transport of tocotrienol is not well 
elucidated and may differ from tocopherol.  Hayes et al. [1993] reported that there 
appears to be a lack of tocotrienols in LDL-C or HDL-C.  They reported that the 
concentration of tocotrienols in platelets was only about 3-5% that of the alpha 
tocopherol, although the platelet concentration of tocotrienols doubled after 
supplementation with palm vitee [tocotrienol enriched palm capsules] in humans.  The 
increase in tocotrienols in platelets was greater than the percentage of increase observed 
for tocopherols.  Suarna et al., [1993] however contradicted Hayes study. Suarna 
reported that after dietary supplementation with mixed tocotrienols, alpha and gamma 
tocotrienols were actually detected in circulating lipoproteins.  Suarna’s study had used 
a sensitive method of detecting tocotrienols that was electrochemical detection 
following chromatographic separation. 
 
    There is currently no data in humans on tissue accumulation of tocotrienols. 
In hamsters, tissue concentrations of tocotrienols were typically much lower than 
tocopherol (1:180 on average) following palm vitee supplementation.  The exception is 
in the adipose tissue where the tocotrienol to tocopherol ratio in supplemented hamsters 
was greater than 1 [Hayes et al., 1993].  The adipose tissue was the only tissue where 
the tocotrienol level exceeds that of tocopherol concentration.   
 
2.2.3.       Storage of vitamin E.  
 
    Vitamin E, as a fat soluble vitamin distributes throughout the body.  The 
human body stores about 40 mg of vitamin E for every kilogram of body weight, where 
